Xeltis is committed to improving the quality of life of patients requiring vascular surgery, such as those in need of hemodialysis vascular access.
These patients, who already face considerable health challenges, struggle with continuous surgical interventions, which can place significant additional burden on them and their families.
The current standard-of-care for vascular surgery is based on materials that have been in use for decades with limited innovation.
Physicians have a choice between animal-derived or synthetic materials which are associated with high rates of rejection, are prone to infection and require additional interventions to maintain their short life span.
Xeltis’ ongoing clinical programs are seeking to address these significant challenges, and offer transformative implants with reduced rates of infection, rejection and need for reintervention.
CLINICAL TRIALS
aXess EU Pivotal Trial 2023
AV Hemodialysis Access Conduit
The aXess pivotal trial is an ongoing research study to investigate how the vascular access conduit aXess works in patients with end-stage kidney disease that need hemodialysis.
Visit Website
aXess EU FIH Study
AV Hemodialysis Access Conduit
A feasibility study to assess the preliminary safety and performance of the Xeltis hemodialysis vascular access conduit (aXess).
Visit Website
XABG/CABG
Coronary Artery Bypass Conduit
Prospective, non-randomized, first in human (FIH) clinical study to assess the feasibility of the novel Xeltis coronary artery bypass conduit (XABG)
Visit Website
Xeltis is a medtech company developing transformative vascular implants that enable the natural creation of living and long-lasting tissue.
Visit our About page to learn more.
About
